It’s pretty clear at this point that the latest class of Alzheimer’s drugs — for all of the headlines, excitement and controversy it’s caused — has limited effectiveness and potentially serious side effects, prompting researchers to look elsewhere.
Eli Lilly’s drug candidate donanemab could soon become the third anti-amyloid monoclonal antibody — which targets a buildup of proteins in the brain thought to contribute to Alzheimer’s — to receive some kind of FDA approval, all in the past three years.
